RANBAXY

Sun Pharmaceutical Industries Limited has submitted to the Exchange vide letter dated March 30, 2015 a copy of disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Members of the Exchange are hereby informed that the trading in equity shares of Ranbaxy Laboratories Limited shall be suspended w.e.f. April 06, 2015 (i.e. closing hours of trading on April 1, 2015) on account of Scheme of Amalgamation with Sun Pharmaceuticals Industries Limited.

Sun Pharmaceuticals Industries Limited has informed the Exchange that the Company has fixed Record Date as April 7, 2015 to determine the names of the shareholders of erstwhile Ranbaxy who would be entitled to receive 8 ( eight) equity shares of Re.1 each of the Company for every 10 (ten) equity shares of Rs.5 each of erstwhile Ranbaxy held and to determine the names of the NCD holders who would be entitled to 1 (One) NCD of Rs.1 lac each of the Company for every 1 (One) NCD of Rs.1 lac each held in erstwhile Ranbaxy pursuant to amalgamation of erstwhile Ranbaxy into the Company.

Ranbaxy Laboratories Limited has informed the Exchange regarding "Intimation about the approval received from Reserve Bank of India and Competition Commission of India in respect of the Scheme of Arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd".

Ranbaxy Laboratories Limited has informed the Exchange that the Hon'ble High Court of Punjab & Haryana has orally pronounced the Order on March 9, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories Ltd. with Sun Pharmaceutical Industries Ltd. under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013. Certified true copy of the Order is awaited.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy loses drug pleas in US". The Company has clarified that "Previously Company has informed the Exchange on November 21, 2014 that the Company had filed a complaint against the US FDA in D.C. Federal Court and in the first instance asking the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided, which was denied. Following that determination, the Court ordered the parties in the suit to prepare and file legal briefs addressi

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy loses drug pleas in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated February 2, 2015, titled "Sun Pharma receives US FTC clearance for Ranbaxy acquisition".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 28, 2015 titled "Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec'14 Sales Rs.81,778 Mn".

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding Stock Exchange Statement dated January 27, 2015 which is being issued by the Company.

Ranbaxy Laboratories Limited has informed that the ESOPs Allotment Committee of Directors at its meeting held on January 22, 2015, allotted 6,40,597 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 425,663,497 Equity Shares of Rs.5 each aggregating Rs. 2,128,317,485/-.

Ranbaxy Laboratories Limited has informed the Exchange that the Trading window will remain closed from January 15, 2015 to January 29, 2015 (both days inclusive) in terms of the provisions of the Company's Code for Prevention for Insider Trading,

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated December 15, 2014 titled "RANBAXY COMMENCES LAUNCH OF INDIA'S FIRST NCE, SYNRIAM IN AFRICAN COUNTRIES".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "EU bans imports from Ranbaxy Unit". The Company has clarified that "The European Medical Agency (EMA) has been referred to as European Authorities in our statement. Further, as informed earlier the Company had decided to stop manufacturing cephalosporin injectables at Dewas much before the inspections by EMA in June, 2014".

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased wi

Ranbaxy Laboratories Limited has informed the Exchange regarding a joint Press Release dated December 8, 2014 titled "CCI approves Ranbaxy acquisition by Sun Pharma".

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to announcement dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy's April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased wi

Ranbaxy Laboratories Limited has informed the Exchange vide Letter dated December 8, 2014 that "On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged that Ranbaxy s April 2008 patent settlement agreement with AstraZeneca concerning esomeprazole magnesium violated U.S. antitrust laws. Ranbaxy is pleased with this verdict, and is committed

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "EU bans imports from Ranbaxy Unit". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Germany bans Ranbaxy drug". The Company has clarified that "The news item is misleading and we wish to clarify as follows in order to place it in the right perspective. The development pertains to only the Company s cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalospo

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "Germany bans Ranbaxy drug". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "CCI wants changes to Sun-Ranbaxy deal". The Company has clarified that "we are in communication with the Competition Commission of India (CCI) on specific products and as of now have not received any final order from the CCI regarding divestment of the products".

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to recent news item captioned "CCI wants changes to Sun-Ranbaxy deal". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information t

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated December 1, 2014, titled "Ranbaxy launches India's first biosimilar of Infliximab drug, InfimabTM".

The Exchange has sought clarification from Ranbaxy Laboratories Limited with respect to news item dated November 27, 2014, captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard the Company has clarified that the news item has primarily quoted clarification issued by the Company on November 21, 2014 in response to the query from NSE. The parties to the suit have filed the Schedule for filing additional legal briefs before the US Court. There is nothing further to provide clarification in the matter.

The Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "US Court refuses Ranbaxy plea to block ANDA for two drugs". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of an

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors at its meeting held on November 25, 2014, allotted 450,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan 2011. The paid-up Equity Share Capital of the Company post allotment is 425,022,900 Equity Shares of Rs.5 each aggregating Rs.2,125

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy fails to block rivals in generic fight". The Company has clarified that " as the Company has earlier informed to the Stock Exchanges that the Company has filed a complaint against the US FDA in D.C. Federal Court and has also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided. The Court has not granted Temporary Restraining Order to block FDA approval for other ANDAs for generic version of Nexium and Valganci

The Exchange has sought clarification Ranbaxy Laboratories Limited with respect to recent news item captioned "Ranbaxy fails to block rivals in generic fight". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any informati

Ranbaxy Laboratories Limited has informed the Exchange regarding the Statement dated November 19, 2014. "Princeton, NJ; Gurgaon, India, November 19, 2014: Following, and in response to, the revocation of Ranbaxy s tentative approvals for Ranbaxy s ANDAs for esomeprazole magnesium delayed-release capsules and valganciclovir hydrochloride tablets, Ranbaxy has filed a complaint against the U.S. FDA in D.C. federal court and has also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy s case is decided."

Ranbaxy Laboratories Limited has informed the Exchange regarding the "Statement" dated November 6, 2014 "Ranbaxy Laboratories Limited (Ranbaxy) has received communication from the US FDA".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated November 5, 2014 titled "Ranbaxy Receives Approval from US FDA to Market Fenofibrate Capsules USP, 43mg and 130mg".

Ranbaxy Laboratories Limited has informed the Exchange that Company have received a letter on October 31, 2014 from the Luxembourg Stock Exchange (LSE) (where GDS of the Company are listed) intimating that in view of the termination of the Deposit Agreement on December 15, 2014, they will de-list the GDS from the official list of the LSE and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014.

Ranbaxy Laboratories Limited has informed the Exchange regarding Press Release dated October 28, 2014, titled "Ranbaxy Q2FY 2015 Sales Rs.32,180Mn. H1 FY2015 Sales Rs.55,902 Mn".

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 22, 2014 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Sun, Ranbaxy may be asked to sell some business for CCI approval to merger". The Company has clarified that "The news article suggests that the Competition Commission of India (CCI) may ask the parties to the merger to sell parts of their businesses as a pre-condition to approve the merger. Further, we wish to clarify that as on date we have not received any such communication from the CCI to divest any part of the business(s). The parties have made certain submissions to the CCI on w

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 11, 2014, alloted 5,59,561 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid- up Equity Share Capital of the Company post allotment is 424,572, 900 Equity Shares of Rs. 5 each aggregating Rs. 2,122,864,500/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 9, 2014 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange regarding press release dated October 1, 2014 titled "Ranbaxy Launches ABSORICA (isotretinoin) 25 mg and 35 mg Capsules in the U.S. Market".

Ranbaxy Laboratories Limited has informed the Exchange that the Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which it reports pricing data for certain products eligible for reimbursement under the Medicaid program. The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation. The Company would fully cooperate with this civil investigation.

The Exchange had sought clarifiation from Ranbaxy Laboratories Limited with respect to a news item captioned "Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor". The Company has clarified that "The Company had in 2008 entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor). This development was communicated to the stock exchanges by the Company vide press release dated June 18, 2008. The lawsuit referred to in the above-referred article was one of the several similar cases filed against the Company and Pfizer Inc

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated September 2, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the Company has received direction vide letter dated August 27, 2014 under Section 29(2) of the Competition Act, 2002 from the Competition Commission of India(CCI) directing the Company to publish the details of the proposed combination in the prescribed format within 10 working days from the date of the said letter of the CCI.

The Exchange had sought clarification from Ranbaxy Laboratories Limited with respect to a news item captioned "Ranbaxy faces Rs 242 cr fine in US for violations at Toansa". The Company has clarified that "The Company is not aware of any demand for fine for violation of the type referred to in the news item. The Company, however, is in discussion with authorities in the US for certain other matters, for which the Company believes, it has made adequate provision in its financial statements declared for the quarter ended till June 30, 2014".

Ranbaxy Laboratories Limited has informed the Exchange that pursuant to an Order dated 5th August, 2014, the Honb'le High Court of Punjab and Haryana at Chandigarh has directed that a meeting of the Equity Shareholders of Ranbaxy Laboratories Limited will be held on 19th September, 2014 for considering Scheme of Arrangement providing inter-alia merger of the Company with Sun Pharmaceutical Industries Limited. In this regard, the Company has submitted a copy of Notice alongwith the explanatory statement as sent to the shareholders for the said meeting.

Ranbaxy Laboratories Limited has informed the Exchange with reference to the Press Release dated July 29, 2014 titled "Ranbaxy Q1 FY 2015 (Apr 14-Jun 14) Sales Rs.23.7 Bn - Growth registered in Base business profitability" issued by the Company. The Company has now informed that the said press release, under the head Key Financial Highlights , inadvertently there was a typo error. The corresponding period for Consolidated sales should be read as Apr-Jun 2013 instead of Jan-Mar 2014 . Accordingly, the revised statement would be as under: Consolidated Sales were Rs.23.7 Bn [Apr-Jun 2013: Sales

Ranbaxy Laboratories Limited has informed the Exchange regarding the details of Voting Results at AGM held on July 28 2014 under Clause 35A of the Listing Agreements

Ranbaxy Laboratories Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.